NasdaqGM:XNCRBiotechs
Does Xencor’s Mixed 2026 Loss Trend Reshape the Investment Narrative Around XNCR’s R&D Priorities?
Xencor, Inc. has reported its second-quarter and half-year 2026 results, with quarterly net loss narrowing to US$21.73 million and basic loss per share from continuing operations improving to US$0.29, while the six-month net loss widened to US$150.65 million and loss per share to US$1.99.
This contrast between an improving second quarter and a much larger year-to-date loss highlights how shifts in spending and development activity are affecting Xencor’s financial profile.
We’ll now examine...